Robert Huizinga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Robert Huizinga has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
M Berry
7 shared publicationsRobert T. Foster
Isotechnika Pharma Inc.; Edmonton Alberta Canada
4 shared publications- Spencer Ling
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada
4 shared publications Launa J. Aspeslet
Isotechnika Pharma Inc.; Edmonton Alberta Canada
3 shared publications- Amit Saxena
Division of Rheumatology New York University New York New York
2 shared publications D.G. Freitag
Isotechnika Pharma Inc., Edmonton, AB, Canada
2 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by Wiley in International Wound Journal
- Vol. 23 (11)
Multidimensional Wound Healing Outcomes in Chronic and Complex Wounds: A Real‐World Case Series With a Thermoreversible Wound Gel
Chronic and complex wounds frequently exhibit delayed healing associated with persistent inflammation, microbial burden and biofilm formation. This prospective observational case series describes wound‐healing outcomes associated with adjunctive use of a thermo‐reversible antimicrobial wound gel (TRG) in 17 adult patients with chronic wounds treated in an outpatient setting. A total of 28 wounds were analysed over up to 12 weeks using clinically relevant endpoints including percentage area reduction (PAR), wound bed tissue composition, exudate level, tissue oxygenation and patient‐reported pain. Mean PAR was 43.9% at the wound level and 42.7% at the patient level. The proportion of wounds demonstrating epithelial tissue increased from 25.0% to 68.8%, while necrotic tissue decreased from 25.0% to 12.5%. Low exudate increased from 41.2% at baseline to 64.7% at final assessment. Mean pain scores decreased from 4.76 to 2.18 ( p = 0.0125). In patients with available tissue oxygenation data, change in oxygenation was positively correlated with PAR ( p = 0.011). These findings suggest that adjunctive use of the TRG was associated with improvement across multiple clinical outcomes in a real‐world population of patients with chronic and complex wounds and support further evaluation in controlled studies.
- 29 October 2026
- Published by Wiley in International Wound Journal
- Vol. 23 (11)
Open AccessMultidimensional Wound Healing Outcomes in Chronic and Complex Wounds: A Real‐World Case Series With a Thermoreversible Wound Gel
Chronic and complex wounds frequently exhibit delayed healing associated with persistent inflammation, microbial burden and biofilm formation. This prospective observational case series describes wound‐healing outcomes associated with adjunctive use of a thermo‐reversible antimicrobial wound gel (TRG) in 17 adult patients with chronic wounds treated in an outpatient setting. A total of 28 wounds were analysed over up to 12 weeks using clinically relevant endpoints including percentage area reduction (PAR), wound bed tissue composition, exudate level, tissue oxygenation and patient‐reported pain. Mean PAR was 43.9% at the wound level and 42.7% at the patient level. The proportion of wounds demonstrating epithelial tissue increased from 25.0% to 68.8%, while necrotic tissue decreased from 25.0% to 12.5%. Low exudate increased from 41.2% at baseline to 64.7% at final assessment. Mean pain scores decreased from 4.76 to 2.18 ( p = 0.0125). In patients with available tissue oxygenation data, change in oxygenation was positively correlated with PAR ( p = 0.011). These findings suggest that adjunctive use of the TRG was associated with improvement across multiple clinical outcomes in a real‐world population of patients with chronic and complex wounds and support further evaluation in controlled studies.
- Open Access
- 15 February 2026
- Published by Wiley in International Wound Journal
- Vol. 23 (2) , e70845
Wound Healing Property of a Novel Thermo‐Reversible Wound Gel With Lasting Antimicrobial and Antibiofilm Activity
This study investigated the efficacy and safety of a novel thermo‐reversible antimicrobial wound gel (TRG, revyve Antimicrobial Wound Gel) designed to combat biofilm‐related infections in wounds. The TRG was evaluated for its ability to disrupt biofilms, sustain antimicrobial activity and promote wound healing. The gel exhibited thermo‐reversible properties, transitioning from a less viscous liquid ≤ 18°C to a highly viscous solid gel at wound temperature which would facilitate easy application and removal. Antimicrobial testing demonstrated that TRG effectively inactivated a broad range of wound‐related pathogens, including Staphylococcus aureus and Pseudomonas aeruginosa , with a 99.99%–99.9999% reduction in bacterial counts within 30 min. The TRG also maintained its antimicrobial efficacy after multiple inoculations with high microbial load (10 7 CFU/mL) over 7 days. In vitro biofilm assays showed effectiveness against biofilm bacteria with a reduction of ≥ 99.99% bacterial counts with one application over the course of 7 days. Biocompatibility testing confirmed that TRG was safe, with no signs of tissue necrosis or signs of tissue damage and no impact on wound healing in a porcine wound model. TRG's ability to reduce both planktonic and biofilm‐based bacteria without compromising wound healing makes it a promising candidate for treating both chronic and acute wounds.
- 15 February 2026
- Published by Wiley in International Wound Journal
- Vol. 23 (2) , e70845
Open AccessWound Healing Property of a Novel Thermo‐Reversible Wound Gel With Lasting Antimicrobial and Antibiofilm Activity
This study investigated the efficacy and safety of a novel thermo‐reversible antimicrobial wound gel (TRG, revyve Antimicrobial Wound Gel) designed to combat biofilm‐related infections in wounds. The TRG was evaluated for its ability to disrupt biofilms, sustain antimicrobial activity and promote wound healing. The gel exhibited thermo‐reversible properties, transitioning from a less viscous liquid ≤ 18°C to a highly viscous solid gel at wound temperature which would facilitate easy application and removal. Antimicrobial testing demonstrated that TRG effectively inactivated a broad range of wound‐related pathogens, including Staphylococcus aureus and Pseudomonas aeruginosa , with a 99.99%–99.9999% reduction in bacterial counts within 30 min. The TRG also maintained its antimicrobial efficacy after multiple inoculations with high microbial load (10 7 CFU/mL) over 7 days. In vitro biofilm assays showed effectiveness against biofilm bacteria with a reduction of ≥ 99.99% bacterial counts with one application over the course of 7 days. Biocompatibility testing confirmed that TRG was safe, with no signs of tissue necrosis or signs of tissue damage and no impact on wound healing in a porcine wound model. TRG's ability to reduce both planktonic and biofilm‐based bacteria without compromising wound healing makes it a promising candidate for treating both chronic and acute wounds.
- Open Access
- 2 May 2025
- Published by Wiley in Arthritis & Rheumatology
- Vol. 77 (10) , 1387-1393
Effect of long‐term voclosporin treatment on renal histology in patients with active lupus nephritis with repeat renal biopsies
Objective: This study characterized the impact of voclosporin on kidney histology in patients with lupus nephritis (LN) who had protocolized repeat kidney biopsies in the AURORA clinical trials.Methods: Patients were randomized to voclosporin or placebo treatment for up to three years; all patients received mycophenolate mofetil and low‐dose glucocorticoids. Patients had baseline kidney biopsies within 6 months prior to study start and repeat biopsies after approximately 18 months of study treatment. The revised NIH indices for LN activity (AI) and chronicity (CI) were calculated, in addition to semi‐quantitative assessment of vascular and tubular lesions.Results: Sixteen patients in the voclosporin group and 10 patients in the control group had both baseline and repeat kidney biopsies. Patient clinical characteristics were similar at baseline. In the voclosporin group, most (n=13) patients had pure class IV lesions (pure class V, n=1; mixed, n=2). In the control group, three patients had pure class IV (pure class III, n=3; pure class V, n=1; mixed, n=3). Most of the voclosporin‐treated patients had no change in CI (n=8) or a change ≤2 (n=6); control‐treated patients also had no change in CI (n=3) or a change ≤2 (n=6). No trends in vascular lesions or tubular compartment changes were observed.Conclusion: Outcomes from this small subgroup show exposure to study treatment was not associated with nephrotoxicity based on histopathologic evaluation after 18 months. These data are reassuring and further contribute to the safety profile of voclosporin for the treatment of adults with active LN.
- 2 May 2025
- Published by Wiley in Arthritis & Rheumatology
- Vol. 77 (10) , 1387-1393
Open AccessEffect of long‐term voclosporin treatment on renal histology in patients with active lupus nephritis with repeat renal biopsies
Objective: This study characterized the impact of voclosporin on kidney histology in patients with lupus nephritis (LN) who had protocolized repeat kidney biopsies in the AURORA clinical trials.Methods: Patients were randomized to voclosporin or placebo treatment for up to three years; all patients received mycophenolate mofetil and low‐dose glucocorticoids. Patients had baseline kidney biopsies within 6 months prior to study start and repeat biopsies after approximately 18 months of study treatment. The revised NIH indices for LN activity (AI) and chronicity (CI) were calculated, in addition to semi‐quantitative assessment of vascular and tubular lesions.Results: Sixteen patients in the voclosporin group and 10 patients in the control group had both baseline and repeat kidney biopsies. Patient clinical characteristics were similar at baseline. In the voclosporin group, most (n=13) patients had pure class IV lesions (pure class V, n=1; mixed, n=2). In the control group, three patients had pure class IV (pure class III, n=3; pure class V, n=1; mixed, n=3). Most of the voclosporin‐treated patients had no change in CI (n=8) or a change ≤2 (n=6); control‐treated patients also had no change in CI (n=3) or a change ≤2 (n=6). No trends in vascular lesions or tubular compartment changes were observed.Conclusion: Outcomes from this small subgroup show exposure to study treatment was not associated with nephrotoxicity based on histopathologic evaluation after 18 months. These data are reassuring and further contribute to the safety profile of voclosporin for the treatment of adults with active LN.
- Open Access
- 27 March 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (3) , e0320662
Synergistic activity of dispersin B and benzoyl peroxide against Cutibacterium acnes/Staphylococcus epidermidis dual-species biofilms
Cutibacterium acnes plays a key role in the development of acne vulgaris, with biofilm formation contributing to its persistence and resistance to antimicrobial treatments. A critical component of C. acnes biofilms is poly-N-acetylglucosamine (PNAG), an exopolysaccharide that facilitates both biofilm stability and biocide resistance. This study evaluated the efficacy of the PNAG-degrading enzyme dispersin B in enhancing the susceptibility of C. acnes biofilms to benzoyl peroxide (BP), a common anti-acne agent. Dual-species biofilms of C. acnes and Staphylococcus epidermidis, which has been shown to promote C. acnes biofilm growth under aerobic conditions, were cultivated in glass tubes and treated with dispersin B (5–80 µg/mL), BP (0.1–2.5%), or a combination of both. Dispersin B or BP alone reduced C. acnes colony-forming units (CFUs) by 1–2 log units. However, sequential treatment with dispersin B followed by BP achieved a synergistic effect, yielding a >6-log reduction in CFUs. Remarkably, concentrations as low as 5 µg/mL dispersin B combined with 0.5% BP efficiently eradicated C. acnes from the dual-species biofilms. These findings highlight the protective role of PNAG against BP and demonstrate the potential of dispersin B as an adjunctive therapy to enhance the efficacy of BP in acne treatment.
- 27 March 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (3) , e0320662
Open AccessSynergistic activity of dispersin B and benzoyl peroxide against Cutibacterium acnes/Staphylococcus epidermidis dual-species biofilms
Cutibacterium acnes plays a key role in the development of acne vulgaris, with biofilm formation contributing to its persistence and resistance to antimicrobial treatments. A critical component of C. acnes biofilms is poly-N-acetylglucosamine (PNAG), an exopolysaccharide that facilitates both biofilm stability and biocide resistance. This study evaluated the efficacy of the PNAG-degrading enzyme dispersin B in enhancing the susceptibility of C. acnes biofilms to benzoyl peroxide (BP), a common anti-acne agent. Dual-species biofilms of C. acnes and Staphylococcus epidermidis, which has been shown to promote C. acnes biofilm growth under aerobic conditions, were cultivated in glass tubes and treated with dispersin B (5–80 µg/mL), BP (0.1–2.5%), or a combination of both. Dispersin B or BP alone reduced C. acnes colony-forming units (CFUs) by 1–2 log units. However, sequential treatment with dispersin B followed by BP achieved a synergistic effect, yielding a >6-log reduction in CFUs. Remarkably, concentrations as low as 5 µg/mL dispersin B combined with 0.5% BP efficiently eradicated C. acnes from the dual-species biofilms. These findings highlight the protective role of PNAG against BP and demonstrate the potential of dispersin B as an adjunctive therapy to enhance the efficacy of BP in acne treatment.
- Open Access
- 12 February 2023
- Published by Wiley in Arthritis Care & Research
- Vol. 75 (7) , 1399-1408
Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis
Objective: This integrated analysis evaluates the efficacy and safety of voclosporin, a novel calcineurin inhibitor, at 23.7 mg twice daily in combination with mycophenolate mofetil (MMF) and oral glucocorticoids in lupus nephritis (LN) using pooled data from two large phase II and phase III clinical trials. The purpose was to expand the pool of patients for safety analyses and to increase power for efficacy analyses in patient subpopulations.Methods: Aurinia Urinary Protein Reduction in Active Lupus with Voclosporin (AURA‐LV) (phase II) and Aurinia Renal Response in Active Lupus With Voclosporin (AURORA 1) (phase III) were randomized, placebo‐controlled, double‐blind trials with similar designs and end points comparing voclosporin to control in combination with MMF and oral glucocorticoids for the treatment of LN. The primary efficacy outcome of the integrated analysis was complete renal response (CRR) at approximately one year (Week 48 data from AURA‐LV and Week 52 from AURORA 1). Safety was assessed throughout the trials.Results: Overall, 534 patients (268 voclosporin; 266 control) were included in the integrated analysis. Significantly more patients achieved a CRR at one year in the voclosporin group than in the control group (43.7% vs. 23.3%; OR 2.76; 95% CI 1.88, 4.05 P < 0.0001). The incidence of adverse events (AEs) was similar (91.4% voclosporin; 87.2% control). Most AEs were mild to moderate in severity; the most commonly reported AEs were classified as infections and infestations (62.2% voclosporin; 54.9% control) and gastrointestinal disorders (45.3% voclosporin; 35.3% placebo). No new or unexpected safety signals were detected.Conclusions: This integrated analysis demonstrates the efficacy and safety of voclosporin in the treatment of LN across the diverse racial and ethnic groups studied.
- 12 February 2023
- Published by Wiley in Arthritis Care & Research
- Vol. 75 (7) , 1399-1408
Open AccessUpdate on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis
Objective: This integrated analysis evaluates the efficacy and safety of voclosporin, a novel calcineurin inhibitor, at 23.7 mg twice daily in combination with mycophenolate mofetil (MMF) and oral glucocorticoids in lupus nephritis (LN) using pooled data from two large phase II and phase III clinical trials. The purpose was to expand the pool of patients for safety analyses and to increase power for efficacy analyses in patient subpopulations.Methods: Aurinia Urinary Protein Reduction in Active Lupus with Voclosporin (AURA‐LV) (phase II) and Aurinia Renal Response in Active Lupus With Voclosporin (AURORA 1) (phase III) were randomized, placebo‐controlled, double‐blind trials with similar designs and end points comparing voclosporin to control in combination with MMF and oral glucocorticoids for the treatment of LN. The primary efficacy outcome of the integrated analysis was complete renal response (CRR) at approximately one year (Week 48 data from AURA‐LV and Week 52 from AURORA 1). Safety was assessed throughout the trials.Results: Overall, 534 patients (268 voclosporin; 266 control) were included in the integrated analysis. Significantly more patients achieved a CRR at one year in the voclosporin group than in the control group (43.7% vs. 23.3%; OR 2.76; 95% CI 1.88, 4.05 P < 0.0001). The incidence of adverse events (AEs) was similar (91.4% voclosporin; 87.2% control). Most AEs were mild to moderate in severity; the most commonly reported AEs were classified as infections and infestations (62.2% voclosporin; 54.9% control) and gastrointestinal disorders (45.3% voclosporin; 35.3% placebo). No new or unexpected safety signals were detected.Conclusions: This integrated analysis demonstrates the efficacy and safety of voclosporin in the treatment of LN across the diverse racial and ethnic groups studied.
- 1 June 2016
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 75 (Suppl 2) , 1049-1050
AB0419 Aurion Study: Preliminary Results of Voclosporin in Lupus Nephritis
Background In lupus nephritis (LN), complete or partial remission (PR) is associated with better patient and renal survival. However, studies demonstrate that subjects who did not achieve a 25% reduction in proteinuria within 8 weeks of starting induction immunosuppression were unlikely to achieve even a PR. Recent studies suggest that a combination of calcineurin inhibitors (CNi's), MMF and low dose steroids may be effective in LN patients. Voclosporin (VCS) is a next generation CNi intended for the treatment of autoimmune diseases and prevention of transplant rejection, with a predictable pharmacokinetic-pharmacodynamic profile. An ongoing study (AURA-LV) is a global double-blind, prospective study comparing 2 doses of VCS with placebo. This study, AURION, is an exploratory study of VCS in active LN in combination with MMF and steroids. Objectives The AURION study assesses the ability of biomarkers measured at 8 weeks to predict clinical response over 24 and 48 weeks. In addition complete remission is assessed at week 24, defined as a protein/creatinine ratio of ≤0.5 mg/mg and estimated glomerular filtration rate (eGFR,CKD-EPI equation) ≥60 mL/min/1.73 m2 or no decrease from baseline in eGFR of ≥20%. Participating subjects with active lupus nephritis will take voclosporin 23.7 mg BID in combination with standard of care. We report preliminary biochemistry data. Methods Eligibility criteria includes: renal biopsy within 2 years of screening; SLE by ACR criteria; laboratory features consistent with active LN; and eGFR >45ml/min/1.73m2. VCS 23.7 mg po BID is administered in combination with MMF 1–2g/day and a reducing course of corticosteroids. UPCr assessments are made at each visit, together with biomarker (C3, C4 and anti-dsDNA) data at regular intervals. Proteinuria reduction over time is presented for the first 7 subjects enrolled in this pilot study, together with renal function, C3, C4 and anti-dsDNA plots. To understand the impact of MMF/steroids alone, UPCr data is presented below with historical data from age/sex/UPCr matched patients from ALMS1. Results (Mean±SD) Pretreatment UPCr was 2.5±1.6 mg/mg and eGFR was 115±34 ml/min. By week 8 mean UPCr had fallen to 0.5±0.5 mg/mg; a reduction in mean UPCr of 81%. eGFR at the same time-point was 113±10 ml/min. Expected increases in C3, C4 and decreases in anti-dsDNA were seen in this population. Baseline demographics Conclusions Preliminary data from this this pilot study indicates that MTT using VCS, in combination with MMF and steroids, produced consistent reductions in proteinuria with preservation of renal function in the first 7 subjects enrolled with active LN. The results of the confirmatory global AURA-LV study using similar treatment patterns will be available later this year. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009 May;20(5):1103–12. Disclosure of Interest R. Yahya Grant/research support from: Aurinia Pharmaceuticals, A. H. B. A. Gafor Grant/research support from: Aurinia Pharmaceuticals, R. Huizinga Shareholder of: Aurinia Pharmaceuticals, Employee of: Aurinia Pharmaceuticals, T. M. Chan Grant/research support from: Aurinia Pharmaceuticals, Consultant for: Aurinia Pharmaceuticals, N. Solomons Shareholder of: Aurinia Pharmaceuticals, Employee of: Aurinia Pharmaceuticals
- 1 June 2016
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 75 (Suppl 2) , 1049-1050
AB0419 Aurion Study: Preliminary Results of Voclosporin in Lupus Nephritis
Background In lupus nephritis (LN), complete or partial remission (PR) is associated with better patient and renal survival. However, studies demonstrate that subjects who did not achieve a 25% reduction in proteinuria within 8 weeks of starting induction immunosuppression were unlikely to achieve even a PR. Recent studies suggest that a combination of calcineurin inhibitors (CNi's), MMF and low dose steroids may be effective in LN patients. Voclosporin (VCS) is a next generation CNi intended for the treatment of autoimmune diseases and prevention of transplant rejection, with a predictable pharmacokinetic-pharmacodynamic profile. An ongoing study (AURA-LV) is a global double-blind, prospective study comparing 2 doses of VCS with placebo. This study, AURION, is an exploratory study of VCS in active LN in combination with MMF and steroids. Objectives The AURION study assesses the ability of biomarkers measured at 8 weeks to predict clinical response over 24 and 48 weeks. In addition complete remission is assessed at week 24, defined as a protein/creatinine ratio of ≤0.5 mg/mg and estimated glomerular filtration rate (eGFR,CKD-EPI equation) ≥60 mL/min/1.73 m2 or no decrease from baseline in eGFR of ≥20%. Participating subjects with active lupus nephritis will take voclosporin 23.7 mg BID in combination with standard of care. We report preliminary biochemistry data. Methods Eligibility criteria includes: renal biopsy within 2 years of screening; SLE by ACR criteria; laboratory features consistent with active LN; and eGFR >45ml/min/1.73m2. VCS 23.7 mg po BID is administered in combination with MMF 1–2g/day and a reducing course of corticosteroids. UPCr assessments are made at each visit, together with biomarker (C3, C4 and anti-dsDNA) data at regular intervals. Proteinuria reduction over time is presented for the first 7 subjects enrolled in this pilot study, together with renal function, C3, C4 and anti-dsDNA plots. To understand the impact of MMF/steroids alone, UPCr data is presented below with historical data from age/sex/UPCr matched patients from ALMS1. Results (Mean±SD) Pretreatment UPCr was 2.5±1.6 mg/mg and eGFR was 115±34 ml/min. By week 8 mean UPCr had fallen to 0.5±0.5 mg/mg; a reduction in mean UPCr of 81%. eGFR at the same time-point was 113±10 ml/min. Expected increases in C3, C4 and decreases in anti-dsDNA were seen in this population. Baseline demographics Conclusions Preliminary data from this this pilot study indicates that MTT using VCS, in combination with MMF and steroids, produced consistent reductions in proteinuria with preservation of renal function in the first 7 subjects enrolled with active LN. The results of the confirmatory global AURA-LV study using similar treatment patterns will be available later this year. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009 May;20(5):1103–12. Disclosure of Interest R. Yahya Grant/research support from: Aurinia Pharmaceuticals, A. H. B. A. Gafor Grant/research support from: Aurinia Pharmaceuticals, R. Huizinga Shareholder of: Aurinia Pharmaceuticals, Employee of: Aurinia Pharmaceuticals, T. M. Chan Grant/research support from: Aurinia Pharmaceuticals, Consultant for: Aurinia Pharmaceuticals, N. Solomons Shareholder of: Aurinia Pharmaceuticals, Employee of: Aurinia Pharmaceuticals
- 22 May 2014
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 77 (6) , 1039-1050
Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin
Voclosporin is a novel calcineurin inhibitor intended for prevention of organ graft rejection and treatment of lupus nephritis. Pharmacokinetic drug interactions between voclosporin and a CYP3A inhibitor, inducer and substrate and a P-glycoprotein inhibitor and substrate were evaluated. Voclosporin 0.4 mg kg(-1) was administered to 24 subjects in each of five studies, as follows: every 12 h (Q12H) alone and concomitantly with ketoconazole 400 mg once daily (QD); single dose before and single dose after rifampin 600 mg QD; Q12H where midazolam 7.5 mg was administered as a single dose alone before voclosporin and with last the dose of voclosporin; Q12H alone and concomitantly with verapamil 80 mg every 8 h; and Q12H with digoxin 0.25 mg QD. The noncompartmental pharmacokinetic parameters maximal concentration (Cmax ) and area under the concentration-time curve (AUC) were obtained, and geometric least squares mean ratios and 90% confidence intervals were evaluated. Ketoconazole increased voclosporin Cmax (6.4-fold) and AUC (18-fold); rifampin reduced voclosporin AUC (0.9-fold); voclosporin did not change exposure of midazolam or α-hydroxy-midazolam; verapamil increased voclosporin Cmax (2.1-fold) and AUC (2.7-fold); and voclosporin increased digoxin Cmax (0.5-fold), AUC (0.25-fold) and urinary excretion (0.2-fold). Administration of voclosporin concomitantly with strong inhibitors and inducers of CYP3A resulted in increased and decreased exposures, respectively, and should be considered contraindicated. Drug-drug interactions involving voclosporin and CYP3A substrates are not expected. Administration of voclosporin concomitantly with inhibitors and substrates of P-glycoprotein resulted in increased voclosporin and substrate exposures, respectively. Appropriate concentration and safety monitoring is recommended with co-administration of voclosporin and P-glycoprotein substrates and inhibitors.
- 22 May 2014
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 77 (6) , 1039-1050
Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin
Voclosporin is a novel calcineurin inhibitor intended for prevention of organ graft rejection and treatment of lupus nephritis. Pharmacokinetic drug interactions between voclosporin and a CYP3A inhibitor, inducer and substrate and a P-glycoprotein inhibitor and substrate were evaluated. Voclosporin 0.4 mg kg(-1) was administered to 24 subjects in each of five studies, as follows: every 12 h (Q12H) alone and concomitantly with ketoconazole 400 mg once daily (QD); single dose before and single dose after rifampin 600 mg QD; Q12H where midazolam 7.5 mg was administered as a single dose alone before voclosporin and with last the dose of voclosporin; Q12H alone and concomitantly with verapamil 80 mg every 8 h; and Q12H with digoxin 0.25 mg QD. The noncompartmental pharmacokinetic parameters maximal concentration (Cmax ) and area under the concentration-time curve (AUC) were obtained, and geometric least squares mean ratios and 90% confidence intervals were evaluated. Ketoconazole increased voclosporin Cmax (6.4-fold) and AUC (18-fold); rifampin reduced voclosporin AUC (0.9-fold); voclosporin did not change exposure of midazolam or α-hydroxy-midazolam; verapamil increased voclosporin Cmax (2.1-fold) and AUC (2.7-fold); and voclosporin increased digoxin Cmax (0.5-fold), AUC (0.25-fold) and urinary excretion (0.2-fold). Administration of voclosporin concomitantly with strong inhibitors and inducers of CYP3A resulted in increased and decreased exposures, respectively, and should be considered contraindicated. Drug-drug interactions involving voclosporin and CYP3A substrates are not expected. Administration of voclosporin concomitantly with inhibitors and substrates of P-glycoprotein resulted in increased voclosporin and substrate exposures, respectively. Appropriate concentration and safety monitoring is recommended with co-administration of voclosporin and P-glycoprotein substrates and inhibitors.
- 30 November 2013
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 54 (5) , 537-545
Population PKPD of voclosporin in renal allograft patients
The aims of this population‐pharmacokinetic/pharmacodynamic (POP‐PKPD) analysis of voclosporin in renal allograft patients were to build a POP‐PKPD model for voclosporin and calcineurin activity (CNa) and identify clinically relevant covariates that could assist dosing of the drug. POP‐PKPD modeling was performed using a stochastic approximation of the standard expectation maximization (SAEM) algorithm for nonlinear mixed‐effects as implemented in Monolix™ 3.2. Voclosporin whole blood concentrations were obtained from de novo renal allograft patients and assayed using a validated LC/MS/MS assay. CNa was measured using a 32P‐radiolabeled assay. A two‐compartment model with simultaneous sigmoid inhibitory Emax model was used to describe the PKPD relationship between voclosporin concentration and CNa. The POP‐PKPD model was then utilized to simulate an optimal initial dosing strategy. Eighty‐seven patients were included in the POP‐PKPD study. Population mean estimates (relative standard error, rse) for oral clearance (CL/F) and first compartment volume of distribution (V1), were 717 mL min−1 (35%) and 2010 mL (17%), respectively. Maximum CNa Inhibition (Imax), effective concentration (C50), and baseline immunosuppression (S0) were 0.87 pmol/min/mg (8.0%), 123 ng/mL (10%), and 1.15 pmol/min/mg (4.0%), respectively. Covariate analyses demonstrated that age and body surface area significantly influenced CL/F: , while serum triglycerides significantly altered S0: .
- 30 November 2013
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 54 (5) , 537-545
Population PKPD of voclosporin in renal allograft patients
The aims of this population‐pharmacokinetic/pharmacodynamic (POP‐PKPD) analysis of voclosporin in renal allograft patients were to build a POP‐PKPD model for voclosporin and calcineurin activity (CNa) and identify clinically relevant covariates that could assist dosing of the drug. POP‐PKPD modeling was performed using a stochastic approximation of the standard expectation maximization (SAEM) algorithm for nonlinear mixed‐effects as implemented in Monolix™ 3.2. Voclosporin whole blood concentrations were obtained from de novo renal allograft patients and assayed using a validated LC/MS/MS assay. CNa was measured using a 32P‐radiolabeled assay. A two‐compartment model with simultaneous sigmoid inhibitory Emax model was used to describe the PKPD relationship between voclosporin concentration and CNa. The POP‐PKPD model was then utilized to simulate an optimal initial dosing strategy. Eighty‐seven patients were included in the POP‐PKPD study. Population mean estimates (relative standard error, rse) for oral clearance (CL/F) and first compartment volume of distribution (V1), were 717 mL min−1 (35%) and 2010 mL (17%), respectively. Maximum CNa Inhibition (Imax), effective concentration (C50), and baseline immunosuppression (S0) were 0.87 pmol/min/mg (8.0%), 123 ng/mL (10%), and 1.15 pmol/min/mg (4.0%), respectively. Covariate analyses demonstrated that age and body surface area significantly influenced CL/F: , while serum triglycerides significantly altered S0: .
- 8 October 2013
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 53 (12) , 1303-1312
Pharmacokinetics of voclosporin in renal impairment and hepatic impairment
Voclosporin is a novel calcineurin inhibitor intended for prevention of organ graft rejection and treatment of lupus nephritis. These studies evaluated the effect of renal or hepatic impairment on pharmacokinetics of voclosporin. Thirty‐three subjects were enrolled into 1 of 4 groups based on renal function as defined by creatinine clearance and 18 subjects were enrolled into 1 of 3 groups based on hepatic function defined by Child‐Pugh classes. Voclosporin 0.4 mg/kg was administered orally. Geometric mean ratios (renal/hepatic impairment‐to‐normal) and 90% confidence intervals for Cmax and AUC were calculated. A default no‐effect interval of 80–125% was set. Although 90% confidence intervals exceeded the no‐effect intervals for both parameters, individual Cmax and AUC plots indicate almost complete overlapping range of values for mild and moderate renal impairment and normal subjects. Severe renal impairment resulted in a 1.5‐fold increase in AUC without an increase in Cmax. Mild to moderate hepatic impairment resulted in a 1.5‐ to 2‐fold increase in voclosporin exposure. Voclosporin can be administered safely to patients with mild to moderate renal impairment without dose modification. Appropriate safety monitoring with concentration‐based adjustments in transplantation are recommended for patients with severe renal impairment, and for patients with hepatic impairment.
- 8 October 2013
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 53 (12) , 1303-1312
Pharmacokinetics of voclosporin in renal impairment and hepatic impairment
Voclosporin is a novel calcineurin inhibitor intended for prevention of organ graft rejection and treatment of lupus nephritis. These studies evaluated the effect of renal or hepatic impairment on pharmacokinetics of voclosporin. Thirty‐three subjects were enrolled into 1 of 4 groups based on renal function as defined by creatinine clearance and 18 subjects were enrolled into 1 of 3 groups based on hepatic function defined by Child‐Pugh classes. Voclosporin 0.4 mg/kg was administered orally. Geometric mean ratios (renal/hepatic impairment‐to‐normal) and 90% confidence intervals for Cmax and AUC were calculated. A default no‐effect interval of 80–125% was set. Although 90% confidence intervals exceeded the no‐effect intervals for both parameters, individual Cmax and AUC plots indicate almost complete overlapping range of values for mild and moderate renal impairment and normal subjects. Severe renal impairment resulted in a 1.5‐fold increase in AUC without an increase in Cmax. Mild to moderate hepatic impairment resulted in a 1.5‐ to 2‐fold increase in voclosporin exposure. Voclosporin can be administered safely to patients with mild to moderate renal impairment without dose modification. Appropriate safety monitoring with concentration‐based adjustments in transplantation are recommended for patients with severe renal impairment, and for patients with hepatic impairment.
- 4 June 2013
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 53 (8) , 819-826
Voclosporin Food Effect and Single Oral Ascending Dose Pharmacokinetic and Pharmacodynamic Studies in Healthy Human Subjects
Voclosporin (VCS) is a novel calcineurin (CN) inhibitor intended for prevention of organ graft rejection and treatment of lupus nephritis. These studies evaluated the single ascending dose pharmacokinetics (PK) and pharmacodynamics (PD, CN activity) of VCS and the effect of food. VCS was administered orally in single doses of 0.25 through 4.5 mg/kg in 62 subjects in the single ascending dose study and as a single oral 1.5 mg/kg dose to 18 subjects after fasting, consumption of a low‐fat and high‐fat meal. Non‐compartmental PK, PD, and PKPD correlation were evaluated. Following single oral doses, systemic exposure increased in a linear manner and demonstrated 1:1 dose‐proportional, first‐order linear PK above 1.5 mg/kg. VCS inhibited CN activity in a dose‐related fashion with maximal inhibition peaking at 3.0 mg/kg. PKPD correlation indicated an EC50 of 78.3 ± 6.8 ng/mL. Administration of VCS with a low‐fat and high‐fat meal decreased Cmax by 29% and 53%, respectively, and AUCinf by 15% and 25%, respectively. Following ascending single doses of VCS, exposure increased in a linear fashion. A food effect on exposure was demonstrated, with a more pronounced effect following a high‐fat meal. VCS concentrations were also found to correlate with CN activity.
- 4 June 2013
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 53 (8) , 819-826
Voclosporin Food Effect and Single Oral Ascending Dose Pharmacokinetic and Pharmacodynamic Studies in Healthy Human Subjects
Voclosporin (VCS) is a novel calcineurin (CN) inhibitor intended for prevention of organ graft rejection and treatment of lupus nephritis. These studies evaluated the single ascending dose pharmacokinetics (PK) and pharmacodynamics (PD, CN activity) of VCS and the effect of food. VCS was administered orally in single doses of 0.25 through 4.5 mg/kg in 62 subjects in the single ascending dose study and as a single oral 1.5 mg/kg dose to 18 subjects after fasting, consumption of a low‐fat and high‐fat meal. Non‐compartmental PK, PD, and PKPD correlation were evaluated. Following single oral doses, systemic exposure increased in a linear manner and demonstrated 1:1 dose‐proportional, first‐order linear PK above 1.5 mg/kg. VCS inhibited CN activity in a dose‐related fashion with maximal inhibition peaking at 3.0 mg/kg. PKPD correlation indicated an EC50 of 78.3 ± 6.8 ng/mL. Administration of VCS with a low‐fat and high‐fat meal decreased Cmax by 29% and 53%, respectively, and AUCinf by 15% and 25%, respectively. Following ascending single doses of VCS, exposure increased in a linear fashion. A food effect on exposure was demonstrated, with a more pronounced effect following a high‐fat meal. VCS concentrations were also found to correlate with CN activity.